Cargando…

Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital

BACKGROUND: Individuals with Schizophrenia Spectrum Disorders (SSD) often experience significant impairment in educational, occupational, and psychosocial functioning. The clinical benefit of long-acting injectable antipsychotics (LAIs) in the management of patients with SSD is well established. SSD...

Descripción completa

Detalles Bibliográficos
Autores principales: Olayinka, Olaniyi, Oyelakin, Ayotomide, Cherukupally, Karthik, Virk, Inderpreet, Ojimba, Chiedozie, Khadka, Susmita, Maksymenko, Alexander, Fouron, Patrice, Khandaker, Taher, Olupona, Tolu, Hershberger, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595334/
https://www.ncbi.nlm.nih.gov/pubmed/31312652
http://dx.doi.org/10.1155/2019/8629030
_version_ 1783430382769668096
author Olayinka, Olaniyi
Oyelakin, Ayotomide
Cherukupally, Karthik
Virk, Inderpreet
Ojimba, Chiedozie
Khadka, Susmita
Maksymenko, Alexander
Fouron, Patrice
Khandaker, Taher
Olupona, Tolu
Hershberger, Jason
author_facet Olayinka, Olaniyi
Oyelakin, Ayotomide
Cherukupally, Karthik
Virk, Inderpreet
Ojimba, Chiedozie
Khadka, Susmita
Maksymenko, Alexander
Fouron, Patrice
Khandaker, Taher
Olupona, Tolu
Hershberger, Jason
author_sort Olayinka, Olaniyi
collection PubMed
description BACKGROUND: Individuals with Schizophrenia Spectrum Disorders (SSD) often experience significant impairment in educational, occupational, and psychosocial functioning. The clinical benefit of long-acting injectable antipsychotics (LAIs) in the management of patients with SSD is well established. SSD patients who are nonadherent to treatment have lower disease relapse and readmission rates when prescribed a LAI, compared to oral antipsychotics. Despite the reported advantages of LAIs, their prescription rates in clinical settings remain low. This pilot study aimed to determine the pattern of LAI prescription in psychiatric inpatients of a teaching community hospital in Brooklyn, New York. METHODS: A retrospective review of the charts of patients discharged from the psychiatric units of the hospital from September 1, 2017, through September 30, 2017, was conducted. Frequencies and proportions for demographic and disease-related characteristics were calculated. Pertinent continuous variables were recoded into categorical variables. Chi-square-tests or Fisher's exact tests were performed for categorical variables. The one-sample Shapiro-Wilk test (for sample size < 50) was used to check for the normality of distribution of continuous variables. Statistical significance was defined as p ≤ 0.05. RESULTS: Forty-three (70%) of the patients discharged from the inpatient unit during the study period had SSD and were eligible for a LAI. Their ages ranged from 20 to 71 years (mean = 41 years), and more than two-thirds were male. Less than half of the eligible patients (n = 19; 44%) were prescribed a LAI, most of whom were male (n=16; 84%). An association between age group (patients aged 41 years or younger) and LAI use was observed (p < 0.05), while gender, employment status, living arrangement, length of hospital stay, recent hospitalization, and cooccurring substance use disorder were not. CONCLUSION: LAI prescription rate at the inpatient psychiatric unit of the hospital was marginally higher than those reported in most studies. Age appears to influence LAI use during the study period. Initiatives that increase LAI prescription rate for all eligible patients admitted to inpatient psychiatric unit should be encouraged.
format Online
Article
Text
id pubmed-6595334
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65953342019-07-16 Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital Olayinka, Olaniyi Oyelakin, Ayotomide Cherukupally, Karthik Virk, Inderpreet Ojimba, Chiedozie Khadka, Susmita Maksymenko, Alexander Fouron, Patrice Khandaker, Taher Olupona, Tolu Hershberger, Jason Psychiatry J Research Article BACKGROUND: Individuals with Schizophrenia Spectrum Disorders (SSD) often experience significant impairment in educational, occupational, and psychosocial functioning. The clinical benefit of long-acting injectable antipsychotics (LAIs) in the management of patients with SSD is well established. SSD patients who are nonadherent to treatment have lower disease relapse and readmission rates when prescribed a LAI, compared to oral antipsychotics. Despite the reported advantages of LAIs, their prescription rates in clinical settings remain low. This pilot study aimed to determine the pattern of LAI prescription in psychiatric inpatients of a teaching community hospital in Brooklyn, New York. METHODS: A retrospective review of the charts of patients discharged from the psychiatric units of the hospital from September 1, 2017, through September 30, 2017, was conducted. Frequencies and proportions for demographic and disease-related characteristics were calculated. Pertinent continuous variables were recoded into categorical variables. Chi-square-tests or Fisher's exact tests were performed for categorical variables. The one-sample Shapiro-Wilk test (for sample size < 50) was used to check for the normality of distribution of continuous variables. Statistical significance was defined as p ≤ 0.05. RESULTS: Forty-three (70%) of the patients discharged from the inpatient unit during the study period had SSD and were eligible for a LAI. Their ages ranged from 20 to 71 years (mean = 41 years), and more than two-thirds were male. Less than half of the eligible patients (n = 19; 44%) were prescribed a LAI, most of whom were male (n=16; 84%). An association between age group (patients aged 41 years or younger) and LAI use was observed (p < 0.05), while gender, employment status, living arrangement, length of hospital stay, recent hospitalization, and cooccurring substance use disorder were not. CONCLUSION: LAI prescription rate at the inpatient psychiatric unit of the hospital was marginally higher than those reported in most studies. Age appears to influence LAI use during the study period. Initiatives that increase LAI prescription rate for all eligible patients admitted to inpatient psychiatric unit should be encouraged. Hindawi 2019-06-13 /pmc/articles/PMC6595334/ /pubmed/31312652 http://dx.doi.org/10.1155/2019/8629030 Text en Copyright © 2019 Olaniyi Olayinka et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Olayinka, Olaniyi
Oyelakin, Ayotomide
Cherukupally, Karthik
Virk, Inderpreet
Ojimba, Chiedozie
Khadka, Susmita
Maksymenko, Alexander
Fouron, Patrice
Khandaker, Taher
Olupona, Tolu
Hershberger, Jason
Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title_full Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title_fullStr Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title_full_unstemmed Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title_short Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
title_sort use of long-acting injectable antipsychotic in an inpatient unit of a community teaching hospital
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595334/
https://www.ncbi.nlm.nih.gov/pubmed/31312652
http://dx.doi.org/10.1155/2019/8629030
work_keys_str_mv AT olayinkaolaniyi useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT oyelakinayotomide useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT cherukupallykarthik useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT virkinderpreet useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT ojimbachiedozie useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT khadkasusmita useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT maksymenkoalexander useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT fouronpatrice useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT khandakertaher useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT oluponatolu useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital
AT hershbergerjason useoflongactinginjectableantipsychoticinaninpatientunitofacommunityteachinghospital